Acute Respiratory Distress Syndrome (ARDS)

LIFE SAVING RESPIRATORY CARE

Acute respiratory distress syndrome (ARDS) is a life-threatening form of non-cardiogenic respiratory failure that affects both children and adults, typically arising in the setting of severe illness, trauma, or sepsis. The syndrome results from diffuse alveolar-capillary membrane damage, triggered by systemic inflammation, aspiration, infection, or trauma. This cascade leads to increased alveolar permeability, pulmonary edema, loss of surfactant, and impaired lung compliance, causing severe ventilation–perfusion (V/Q) mismatch and hypoxemia. The consequences include multiorgan dysfunction, prolonged mechanical ventilation, and high mortality, with survivors at risk for long-term pulmonary and neurocognitive impairments.

Key Facts:

  • Epidemiology: Affects ~10% of all ICU patients worldwide, with an estimated 3 million cases annually; mortality remains 30–45%, rising to >50% in severe cases.
  • Unmet Need: No disease-modifying therapies; treatment is limited to supportive measures such as lung-protective ventilation, prone positioning, and conservative fluid management.
  • Economic Burden: ICU care for ARDS patients often exceeds $3,500–$4,000 per day, with extended critical care stays and long-term rehabilitation driving multi-billion-dollar healthcare costs annually.
  • Clinical Opportunity: Zelpultide alfa is being investigated as a potential therapy to restore alveolar function and reduce mortality.
  • Investor Opportunity: High clinical need and absence of targeted therapies create significant market potential, with emerging therapies projected to reach multi-billion-dollar sales if they demonstrate mortality benefit or reduction of long-term disability.